STOCK TITAN

Astria Therapeutics Inc - ATXS STOCK NEWS

Welcome to our dedicated news page for Astria Therapeutics (Ticker: ATXS), a resource for investors and traders seeking the latest updates and insights on Astria Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Astria Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Astria Therapeutics's position in the market.

Rhea-AI Summary
Astria Therapeutics (ATXS) to Present STAR-0215 Phase 1a Results at World Allergy Congress
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.73%
Tags
conferences
-
Rhea-AI Summary
Astria Therapeutics, Inc. (ATXS) CEO Jill C. Milne, Ph.D., to present corporate overview and information on STAR-0215 and STAR-0310 at 6th Annual Evercore ISI HealthCONx Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
Astria Therapeutics, Inc. (ATXS) Reports Positive Phase 1a Results for STAR-0215 and Plans for STAR-0310 IND Submission and ALPHA-STAR Trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.39%
Tags
Rhea-AI Summary
Astria Therapeutics, Inc. (Nasdaq:ATXS) presents new STAR-0215 data at ACAAI, confirming its potential as a long-acting preventative therapy for Hereditary Angioedema (HAE). The data show robust attack suppression and low treatment burden, supporting the vision for STAR-0215 as a first-choice therapy for HAE. The Phase 1b/2 ALPHA-STAR trial is on track, with initial proof-of-concept data expected in Q1 2024. STAR-0215 was well-tolerated with no serious adverse events, achieving potentially therapeutic levels in less than one day and showing an estimated half-life of up to 127 days. Pharmacokinetic and pharmacodynamic data demonstrate early proof-of-concept as a potential HAE therapy with favorable safety profile, long half-life, and durable PD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.86%
Tags
-
Rhea-AI Summary
Astria Therapeutics, Inc. (Nasdaq:ATXS) announces CEO Dr. Jill C. Milne's presentation on STAR-0215 and STAR-0310 at Jefferies London Healthcare Conference. Webcast available at https://wsw.com/webcast/jeff287/atxs/1884032. Archived replay on www.astriatx.com for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.49%
Tags
conferences
-
Rhea-AI Summary
Astria Therapeutics, Inc. (Nasdaq:ATXS) will present new STAR-0215 data at the American College of Allergy, Asthma, and Immunology Annual Scientific Meeting. Dr. William Lumry will share additional data from the Phase 1a clinical trial of STAR-0215 in a poster presentation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.41%
Tags
conferences
Rhea-AI Summary
Astria Therapeutics, Inc. (Nasdaq:ATXS) granted stock options to purchase 36,800 shares of common stock to two new employees under its 2022 Inducement Stock Incentive Plan. The options have an exercise price of $4.76, vest over four years, and are subject to continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.41%
Tags
none
-
Rhea-AI Summary
Astria Therapeutics, Inc. (Nasdaq:ATXS) will report its third quarter 2023 financial results on November 13, 2023. The Chief Executive Officer, Jill C. Milne, will host a conference call and webcast at 8:30am ET to discuss the results and provide an update on corporate developments. Interested parties can join the webcast via the Astria website or the provided link.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.06%
Tags
conferences earnings
-
Rhea-AI Summary
Astria Therapeutics announces pricing of underwritten offering, expecting to raise approximately $64 million
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
none
Rhea-AI Summary
Astria Therapeutics announces exclusive license agreement with Ichnos Sciences for potential treatment of atopic dermatitis
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
none
Astria Therapeutics Inc

Nasdaq:ATXS

ATXS Rankings

ATXS Stock Data

609.42M
36.14M
0.49%
88.01%
9.22%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Boston